GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Net Income (Discontinued Operations)

PRME (Prime Medicine) Net Income (Discontinued Operations) : $0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Net Income (Discontinued Operations)?

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods. Prime Medicine's Net Income (Discontinued Operations) for the three months ended in Mar. 2025 was $0.00 Mil. Its Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil.


Prime Medicine Net Income (Discontinued Operations) Historical Data

The historical data trend for Prime Medicine's Net Income (Discontinued Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Net Income (Discontinued Operations) Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income (Discontinued Operations)
- - - - -

Prime Medicine Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Income (Discontinued Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Prime Medicine Net Income (Discontinued Operations) Calculation

Net Income (Discontinued Operations) indicates the net income that a firm brought in from operations that will not be used in future reporting periods.

Net Income (Discontinued Operations) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prime Medicine Net Income (Discontinued Operations) Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Net Income (Discontinued Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Prime Medicine Business Description

Industry
Traded in Other Exchanges
N/A
Address
60 First Street, Cambridge, MA, USA, 02141
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Ann L. Lee officer: Chief Technical Officer 400 DEXTER AVENUE NORTH, SUITE 1200, SEATTLE WA 98109
Richard Brudnick officer: Chief Business Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Steven Gillis 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139

Prime Medicine Headlines

From GuruFocus